Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...

The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development ...

Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net ...

As with other drugs, Hizentra (immune globulin subcutaneous [human]) can cause side effects, such as headache and fatigue (low energy). If side effects of Hizentra become difficult to tolerate, talk ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, was not only 100% successfully self-administered subcutaneously in a new ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...